These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 10204943)
1. Tumour volume as a predictor of necrosis after chemotherapy in Ewing's sarcoma. Abudu A; Davies AM; Pynsent PB; Mangham DC; Tillman RM; Carter SR; Grimer RJ J Bone Joint Surg Br; 1999 Mar; 81(2):317-22. PubMed ID: 10204943 [TBL] [Abstract][Full Text] [Related]
2. Multiparametric MRI with diffusion-weighted imaging in predicting response to chemotherapy in cases of osteosarcoma and Ewing's sarcoma. Saleh MM; Abdelrahman TM; Madney Y; Mohamed G; Shokry AM; Moustafa AF Br J Radiol; 2020 Nov; 93(1115):20200257. PubMed ID: 32706980 [TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities. Picci P; Rougraff BT; Bacci G; Neff JR; Sangiorgi L; Cazzola A; Baldini N; Ferrari S; Mercuri M; Ruggieri P J Clin Oncol; 1993 Sep; 11(9):1763-9. PubMed ID: 8355043 [TBL] [Abstract][Full Text] [Related]
4. Prognostic factors in patients with localized Ewing's sarcoma: the effect on survival of actual received drug dose intensity and of histologic response to induction therapy. Delepine N; Delepine G; Cornille H; Voisin MC; Brun B; Desbois JC J Chemother; 1997 Oct; 9(5):352-63. PubMed ID: 9373791 [TBL] [Abstract][Full Text] [Related]
5. Classification of histopathologic changes following chemotherapy in Ewing's sarcoma of bone. van der Woude HJ; Bloem JL; Taminiau AH; Nooy MA; Hogendoorn PC Skeletal Radiol; 1994 Oct; 23(7):501-7. PubMed ID: 7824975 [TBL] [Abstract][Full Text] [Related]
6. Monitoring the effect of chemotherapy in Ewing's sarcoma of bone with MR imaging. van der Woude HJ; Bloem JL; Holscher HC; Nooy MA; Taminiau AH; Hermans J; Falke TH; Hogendoorn PC Skeletal Radiol; 1994 Oct; 23(7):493-500. PubMed ID: 7824974 [TBL] [Abstract][Full Text] [Related]
7. Ewing's sarcoma: only patients with 100% of necrosis after chemotherapy should be classified as having a good response. Albergo JI; Gaston CL; Laitinen M; Darbyshire A; Jeys LM; Sumathi V; Parry M; Peake D; Carter SR; Tillman R; Abudu AT; Grimer RJ Bone Joint J; 2016 Aug; 98-B(8):1138-44. PubMed ID: 27482030 [TBL] [Abstract][Full Text] [Related]
8. Prognostic factors and patterns of relapse in ewing sarcoma patients treated with chemotherapy and r0 resection. Pan HY; Morani A; Wang WL; Hess KR; Paulino AC; Ludwig JA; Lin PP; Daw NC; Mahajan A Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):349-57. PubMed ID: 25772182 [TBL] [Abstract][Full Text] [Related]
9. Prognostic features of Ewing's sarcoma on radionuclide bone scan after initial treatment. Reinus WR; Gilula LA; Donaldson SS; Shuster J; Vietti T Eur J Radiol; 1994 Nov; 19(1):1-6. PubMed ID: 7859751 [TBL] [Abstract][Full Text] [Related]
10. Imaging of malignant tumours of the long bones in children: monitoring response to neoadjuvant chemotherapy and preoperative assessment. Brisse H; Ollivier L; Edeline V; Pacquement H; Michon J; Glorion C; Neuenschwander S Pediatr Radiol; 2004 Aug; 34(8):595-605. PubMed ID: 15103428 [TBL] [Abstract][Full Text] [Related]
11. Ewing's sarcoma of the ribs. A report from the cooperative Ewing's sarcoma study. Ozaki T; Lindner N; Hoffmann C; Hillmann A; Rödl R; Blasius S; Link T; Winkelmann W; Jürgens H Eur J Cancer; 1995 Dec; 31A(13-14):2284-8. PubMed ID: 8652257 [TBL] [Abstract][Full Text] [Related]
13. Osteosarcoma and Ewing's sarcoma after neoadjuvant chemotherapy: value of dynamic MR imaging in detecting viable tumor before surgery. van der Woude HJ; Bloem JL; Verstraete KL; Taminiau AH; Nooy MA; Hogendoorn PC AJR Am J Roentgenol; 1995 Sep; 165(3):593-8. PubMed ID: 7645476 [TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. Bacci G; Ferrari S; Bertoni F; Rimondini S; Longhi A; Bacchini P; Forni C; Manfrini M; Donati D; Picci P J Clin Oncol; 2000 Jan; 18(1):4-11. PubMed ID: 10623687 [TBL] [Abstract][Full Text] [Related]
15. Risk analysis factors for local recurrence in Ewing's sarcoma: when should adjuvant radiotherapy be administered? Albergo JI; Gaston CLL; Parry MC; Laitinen MK; Jeys LM; Tillman RM; Abudu AT; Grimer RJ Bone Joint J; 2018 Feb; 100-B(2):247-255. PubMed ID: 29437069 [TBL] [Abstract][Full Text] [Related]
16. Predictive factors of histological response to primary chemotherapy in Ewing's sarcoma. Bacci G; Picci P; Mercuri M; Ferrari S; Longhi A; Cesari M; Rosito P; Mancini AF; Barbieri E; Baldini N Acta Oncol; 1998; 37(7-8):671-6. PubMed ID: 10050985 [TBL] [Abstract][Full Text] [Related]
17. Hypoalbuminaemia is an independent predictor of poor outcome in metastatic Ewing's sarcoma family of tumours: a single institutional experience of 150 cases treated with uniform chemotherapy protocol. Biswas B; Rastogi S; Khan SA; Shukla NK; Deo SV; Agarwala S; Sharma DN; Thulkar S; Vishnubhatla S; Pathania S; Bakhshi S Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):722-9. PubMed ID: 24919857 [TBL] [Abstract][Full Text] [Related]
18. Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity. Ferrari S; Mercuri M; Rosito P; Mancini A; Barbieri E; Longhi A; Rimondini S; Cesari M; Ruggieri P; Di Liddo M; Bacci G J Chemother; 1998 Dec; 10(6):484-91. PubMed ID: 9876058 [TBL] [Abstract][Full Text] [Related]
19. A multidisciplinary study investigating radiotherapy in Ewing's sarcoma: end results of POG #8346. Pediatric Oncology Group. Donaldson SS; Torrey M; Link MP; Glicksman A; Gilula L; Laurie F; Manning J; Neff J; Reinus W; Thompson E; Shuster JJ Int J Radiat Oncol Biol Phys; 1998 Aug; 42(1):125-35. PubMed ID: 9747829 [TBL] [Abstract][Full Text] [Related]
20. Histological response to neoadjuvant chemotherapy in localized Ewing sarcoma of the bone: A retrospective analysis of available scoring tools. Righi A; Pacheco M; Palmerini E; Carretta E; Gambarotti M; Longhi A; Magagnoli G; Sbaraglia M; Manfrini M; Picci P; Dei Tos AP Eur J Surg Oncol; 2021 Jul; 47(7):1778-1783. PubMed ID: 33622576 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]